Physician profile
Sara S Cooley
NPI 1164891438
$1,279.73
in general payments reported to CMS, 2019-2025
20 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $332 · 2023: $232 · 2024: $146 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $257.04 | 2021-2025 | |
| Amgen INC. | $166.34 | 2021-2025 | Evenity, Prolia |
| Novo Nordisk INC | $126.63 | 2021-2024 | Rybelsus, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.31 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.10 | 2021-2024 | Xifaxan |
| Daiichi Sankyo INC. | $96.79 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $69.03 | 2023-2024 | Evusheld, Flumist Quadrivalent, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.90 | 2021-2023 | Ofev |
| Otsuka America Pharmaceutical, INC. | $54.40 | 2023 | Rexulti |
| Nestle Healthcare Nutrition INC. | $39.08 | 2021 | |
| Avanir Pharmaceuticals, INC. | $35.34 | 2021 | |
| Pfizer INC. | $33.30 | 2024 | |
| Scilex Pharmaceuticals INC. | $32.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.86 | 2021 | |
| Mylan Specialty L.P. | $18.76 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $18.09 | 2022 | |
| Becton, Dickinson and Company | $15.10 | 2023 | Bd Onclarity |
| Glaxosmithkline, LLC. | $13.32 | 2022 | |
| Lilly USA, LLC | $12.26 | 2021 | |
| Genentech USA, INC. | $7.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Cooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.